Things You Didn’t Know About SLT - Takeaways - MDSpire

Things You Didn’t Know About SLT

Experienced surgeons dispel myths about selective laser trabeculoplasty and provide pearls and practice insights.

  • By

  • Syril K. Dorairaj, MD, and

  • Ariana Levin, MD

  • Tony Realini, MD, MPH

  • Constance O. Okeke, MD, MSCE

  • Steven R. Sarkisian, Jr., MD

  • Christine Funke, MD

  • Lorraine M. Provencher, MD

  • Marlene R. Moster, MD

  • Shivani S. Kamat, MD

  • Sahar Bedrood, MD, PhD

  • Douglas J. Rhee, MD

  • Jacob W. Brubaker, MD

  • Kateki Vinod, MD

  • Lauren S. Blieden, MD

  • Mary Qiu, MD,

  • Samantha Goldburg, MD

  • John Berdahl, MD

  • March 1, 2026

  • 18 min

Share

  • 1

    Selective laser trabeculoplasty (SLT) is gaining recognition as a first-line therapy for glaucoma, showing durable efficacy and cost-effectiveness.

  • 2

    SLT can improve ocular surface health and quality of life by reducing the need for topical medications, not just lowering intraocular pressure.

  • 3

    Effective patient communication about SLT is crucial; framing it as 'light energy treatment' can increase patient acceptance and understanding.

  • 4

    SLT is underutilized in uveitic eyes, but can be beneficial when managed carefully with uveitis specialists and appropriate post-procedure care.

  • 5

    Despite evidence supporting primary SLT, its adoption remains slow, highlighting the need for a shift in clinical practice and patient education.

Original Source(s)

Things You Didn’t Know About SLT

  • by Syril K. Dorairaj, MD, and, Ariana Levin, MD, Tony Realini, MD, MPH, Constance O. Okeke, MD, MSCE, Steven R. Sarkisian, Jr., MD, Christine Funke, MD, Lorraine M. Provencher, MD, Marlene R. Moster, MD, Shivani S. Kamat, MD, Sahar Bedrood, MD, PhD, Douglas J. Rhee, MD, Jacob W. Brubaker, MD, Kateki Vinod, MD, Lauren S. Blieden, MD, Mary Qiu, MD,, Samantha Goldburg, MD, John Berdahl, MD

  • March 1, 2026

Related Content

The Unmeasured Burden of Glaucoma

What do glaucoma patients talk about outside of the clinic?

Do Systemic Alpha-2 Agonists Lower Glaucoma Risk?

A large US cohort study found systemic alpha-2 agonist use was associated with a lower hazard of glaucoma-related diagnoses vs. beta-blockers.

Taking FLIGHT

ViaLase announces first commercial FLIGHT procedures in Europe

  • June 18, 2026

  • 2 min